B. Riley raised the firm’s price target on Azenta to $79 from $61 and keeps a Buy rating on the shares. The analyst anticipates the service demand from cell and gene therapy developers to recover slowly as the capital market opens and investment from big pharma in CAR T increases.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on AZTA:
